Medicine and Dentistry
Hepatocellular Carcinoma
100%
Immune Checkpoint Inhibitor
100%
Clinical Trial
100%
Monotherapy
60%
Angiogenesis Inhibitor
40%
Nivolumab
40%
Sorafenib
40%
Atezolizumab
40%
Diseases
20%
Drug Therapy
20%
Biological Marker
20%
CTLA-4
20%
English (Language)
20%
Supportive Care
20%
Liver Function
20%
Local Therapy
20%
Tumor Regression
20%
Programmed Death-Ligand 1
20%
Tumor Immunity
20%
Arm
20%
Ipilimumab
20%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
100%
Clinical Trial
100%
Liver Cell Carcinoma
100%
Monotherapy
60%
Angiogenesis Inhibitor
40%
Bevacizumab
40%
Sorafenib
40%
Nivolumab
40%
Atezolizumab
40%
Cytotoxic T Lymphocyte Antigen 4
20%
Disease
20%
Biological Marker
20%
Neoplasm
20%
Tumor Regression
20%
Ipilimumab
20%
Pembrolizumab
20%
Keyphrases
CTLA-4 Inhibitors
20%
Tumor Remission
20%
Atezolizumab Plus Bevacizumab
20%
PD-L1 Inhibitor
20%